Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1752828 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $0.67Day −11.84%Mkt cap $19M1Y −79.0%Off 52W high −84.5%Vol (1Y) 91.5%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,259 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest1.4% of sh out |
| Days to cover2.9d |
| 13F net flow (QoQ)+0.08% |
| Top-10 13F concentration92.7% |
| Next report (est.)2026-09-17 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$26.6M |
| Earnings (TTM)-$91.7M |
| Net margin−345.4% |
| Sales growth 3Y13.9% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−39.6% |
| 1Y−79.0% |
| 3Y−83.5% |
| 5Y−99.2% |
| Since incept. (ann.)−63.8% |
Total return through 2026-07-29 · series begins 2021-07-20. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)91.5% |
| Ann. volatility (3Y)130.8% |
| Sharpe (1Y)−1.29 |
| Sharpe (3Y)0.12 |
| Max drawdown (1Y)−85.6% |
| Max drawdown (3Y)−91.4% |
| Beta (3Y vs SPY)1.36 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| C V STARR & CO INC | 764,069 | $1M | 2.64% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 621,105 | $826,070 | 2.15% | new |
| GEODE CAPITAL MANAGEMENT, LLC | 191,076 | $254,171 | 0.66% | +19.3% |
| BlackRock, Inc. | 127,501 | $169,575 | 0.44% | +11.0% |
| VANGUARD FIDUCIARY TRUST CO | 79,874 | $106,232 | 0.28% | new |
| STATE STREET CORP | 57,830 | $76,914 | 0.20% | +0.0% |
| Valmark Advisers, Inc. | 49,983 | $66,477 | 0.17% | +0.0% |
| NORTHERN TRUST CORP | 44,163 | $58,737 | 0.15% | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2025-12-31 | 2026-04-30 | — | — | $4.1M | −77.4% |
| 2025-09-30 | 2025-11-14 | −$0.88 | — | $5.3M | −43.2% |
| 2025-06-30 | 2025-08-29 | −$1.02 | — | $5.7M | −52.6% |
| 2025-03-31 | 2025-05-09 | −$0.84 | — | $11.4M | −22.2% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-09-17 is ESTIMATED from filing cadence (median gap 140d) — not company-confirmed.
Degenerative Disease 65% · Biobanking 20% · Cell Therapy 14%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
